ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Pharmaceuticals, Inc. (ORIC) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (D+). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | D+ (1.6) | C- (2.1) | B- (2.9) | C+ (2.6) | C (2.3) |
| 2026-11-07 | C+ (2.5) | D+ (1.6) | C- (2.1) | C+ (2.8) | C+ (2.7) | C (2.3) |
| 2026-10-31 | C+ (2.5) | D+ (1.5) | C (2.3) | B- (3.1) | C+ (2.7) | C (2.4) |
| 2026-10-24 | C+ (2.5) | D+ (1.5) | C (2.2) | B (3.3) | C+ (2.6) | C (2.4) |
| 2026-10-17 | C+ (2.5) | D+ (1.5) | C (2.2) | B (3.3) | C+ (2.6) | C (2.4) |